Lilly retatrutide trial shows 28 percent weight loss
Eli Lilly reported its experimental drug retatrutide helped patients lose 28.3 percent of body weight over 80 weeks. The firm plans a market launch next year.
Xurve View
Insights:
Xurve View
ELI LILLY & CO reported that its experimental drug retatrutide helped patients lose 28.3% of their body weight over 80 weeks. The late-stage trial results for the "triple G" medication exceed the 15-20% weight loss typically seen with current market leaders. This data strengthens Lilly's position to challenge the dominance of NOVO-NORDISK A/S-SPONS ADR in the global obesity market.
